All In Biotech

Drug Trial Radar · NCT03448549

SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients

A Prospective Randomized Controlled Trial to Compare Oxaliplatin Combined With S-1 (SOX) Versus Oxaliplatin With Capecitabine (XELOX) as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients

Last checked: Nov 19, 2026Latest source record: Mar 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 1,191 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,191

Planned (sponsor's estimate)

Start

Jan 1, 2018

Primary completion

Jan 1, 2021

Study completion Jan 1, 2024

Sponsor

Lead sponsor
Peking University Cancer Hospital & InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Peking Union Medical College Hospital; Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Peking University People's Hospital
First posted
Feb 28, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Fluorouracil combined with oxaliplatin are routinely recommended to patients with pathological stage III (p-stage III) colorectal cancer, leading to significant improvement of 5-year disease-free survival and overall survival (approximately 3.4% -4.2%) by by international guidelines such as the National Cancer Comprehensive Network. The Considerable proportion of patients suffer with hand-foot syndrome due to capecitabine as commonly prescribed. Meanwhile as another agent of fluorouracil, tegafur,gimeracil and oteracil potassium (short for TGOP) has been shown with similar effect and less adverse reaction. This study was designed to investigate the short-term and long-term safety and efficacy of TGOP-OX and XELOX regimens in colorectal cancer p-stage III patients who undergo curative surgery and adjuvant chemotherapy, and to explore the compliance and quality of life in patients treated with TGOP-OX regime.

Conditions

  • Colorectal Cancer Stage III
  • Adjuvant Chemotherapy

Interventions

  • OxaliplatinDrug

    adjuvant chemotherapy

  • Tegafur,gimeracil and oteracil potassiumDrug

    adjuvant chemotherapy

  • XelodaDrug

    adjuvant chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 3 year disease free survivalTime frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.